和铂医药-B(02142)旗下公司与业务伙伴订立授权及合作协议，以推进治疗多种疾病的促皮质素释放激素(CRH)的新型疗法

智通财经02-26

智通财经APP讯，和铂医药-B(02142)公布，公司孵化的创新型生物技术公司HBM Alpha Therapeutics(HBMAT)已与一名业务伙伴订立授权及合作协议，以推进治疗多种疾病的促皮质素释放激素(CRH)的新型疗法。根据该协议，业务伙伴获授予在全球范围内(不包括大中华区，即中国大陆、中国台湾、中国香港及中国澳门)开发任何包含或含有HBM9013的医药产品的独家授权。根据该协议的条款，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2514261560?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-02-26 08:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514261560","market":"us","top_or_hot":-1,"title":"和铂医药-B(02142)旗下公司与业务伙伴订立授权及合作协议，以推进治疗多种疾病的促皮质素释放激素(CRH)的新型疗法","media":"智通财经","content":"<div>\n<p>智通财经APP讯，和铂医药-B(02142)公布，公司孵化的创新型生物技术公司HBM Alpha Therapeutics(HBMAT)已与一名业务伙伴订立授权及合作协议，以推进治疗多种疾病的促皮质素释放激素(CRH)的新型疗法。根据该协议，业务伙伴获授予在全球范围内(不包括大中华区，即中国大陆、中国台湾、中国香港及中国澳门)开发任何包含或含有HBM9013的医药产品的独家授权。根据该协议的条款，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1254377.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>和铂医药-B(02142)旗下公司与业务伙伴订立授权及合作协议，以推进治疗多种疾病的促皮质素释放激素(CRH)的新型疗法</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n和铂医药-B(02142)旗下公司与业务伙伴订立授权及合作协议，以推进治疗多种疾病的促皮质素释放激素(CRH)的新型疗法\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-26 08:06 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1254377.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，和铂医药-B(02142)公布，公司孵化的创新型生物技术公司HBM Alpha Therapeutics(HBMAT)已与一名业务伙伴订立授权及合作协议，以推进治疗多种疾病的促皮质素释放激素(CRH)的新型疗法。根据该协议，业务伙伴获授予在全球范围内(不包括大中华区，即中国大陆、中国台湾、中国香港及中国澳门)开发任何包含或含有HBM9013的医药产品的独家授权。根据该协议的条款，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1254377.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1267930573.SGD","symbol_name":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1254377.html","article_id":"2514261560","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514261560","pubTimestamp":1740528375,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，和铂医药-B 公布，公司孵化的创新型生物技术公司HBM Alpha Therapeutics已与一名业务伙伴订立授权及合作协议，以推进治疗多种疾病的促皮质素释放激素的新型疗法。HBM9013/HAT001是该集团开发的一项抗CRH抗体疗程，旨在治疗CRH相关疾病，包括先天性肾上腺增生症及其他疾病。目前，CAH的治疗选择有限，导致对创新疗法的重大未满足医疗需求。HBM9013/HAT001已在下调CRH介导的促肾上腺皮质激素诱导方面显示出强大的临床前疗效，并正在向临床开发推进。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU1019634622.SGD":"Blackrock European Equity Income A6 SGD-H","LU0314106906.USD":"MANULIFE GF GLOBAL EQUITY \"AA\" (USD) INC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","BK1574":"生物医药B类股","LU1880398554.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) INC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU1880398471.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","BK1583":"高瓴概念","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU2092937221.SGD":"Blackrock Circular Economy A2 SGD-H","LU0942090050.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD)  INC","BK4011":"建筑材料","LU1863844665.USD":"TEMPLETON EUROLAND \"A\" (USD) ACC A","LU2463526074.USD":"NORDEA 1 - GLOBAL CLIMATE ENGAGEMENT \"BP\" (USD) ACC","LU1863844749.USD":"TEMPLETON EUROLAND \"A\" (USD) INC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU2360108059.USD":"BGF CIRCULAR ECONOMY \"A4\" (USD) INC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU0868494708.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC","LU2298321311.HKD":"BGF CIRCULAR ECONOMY \"A\" (HKDHDG) ACC","LU1291149836.SGD":"Janus Henderson Horizon Euroland A2 SGD-H","CRH":"CRH水泥","LU2041044095.USD":"Blackrock Circular Economy A2 USD","BK1161":"生物科技","02142":"和铂医药-B","LU1035777561.USD":"AB SICAV I - EUROPEAN EQUITY PORTFOLIO \"A\" (USDHDG) ACC","LU1019632923.USD":"Blackrock European Equity Income A6 USD-H","LU1039938227.USD":"Janus Henderson Horizon Euroland A2 USD-H"},"translate_title":"Hebo Pharmaceuticals-B (02142) companies have entered into licensing and cooperation agreements with business partners to advance novel corticotropin-releasing hormone (CRH) therapies for the treatment of various diseases","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":1,"CRH":1},"content_text":"智通财经APP讯，和铂医药-B(02142)公布，公司孵化的创新型生物技术公司HBM Alpha Therapeutics(HBMAT)已与一名业务伙伴订立授权及合作协议，以推进治疗多种疾病的促皮质素释放激素(CRH)的新型疗法。根据该协议，业务伙伴获授予在全球范围内(不包括大中华区，即中国大陆、中国台湾、中国香港及中国澳门)开发任何包含或含有HBM9013的医药产品的独家授权。根据该协议的条款，HBMAT有权获得总计高达3.95亿美元的首付款及潜在里程碑付款，以及于特许使用权期限内基于净销售额的个位数百分比的分级特许权使用费。此外，HBMAT亦有权获得认股权证以收取业务伙伴的少数股权。据悉，HBM Alpha Therapeutics是一家开发针对罕见遗传疾病先天性肾上腺增生症(CAH) 和多囊型卵巢综合症(PCOS)抗体疗法的公司，其疗法亦适用于与下丘脑-垂体-肾上腺轴(HPA)调节及功能异常相关的其他内分泌疾病。HBMAT于2019年在美国特拉华州注册成立，是和铂医药与哈佛医学院附属医院波士顿儿童医院的合资企业。HBM9013/HAT001是该集团开发的一项抗CRH抗体疗程，旨在治疗CRH相关疾病，包括先天性肾上腺增生症(CAH)及其他疾病。CAH是一组常染色体隐性遗传疾病，由于编码关键肾上腺激素合成所需酶的基因突变引起，这些突变会导致严重的健康后果。目前，CAH的治疗选择有限，导致对创新疗法的重大未满足医疗需求。HBM9013/HAT001已在下调CRH介导的促肾上腺皮质激素(ACTH)诱导方面显示出强大的临床前疗效，并正在向临床开发推进。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2514261560"}